

Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

**Labixxin 100mg/ml solution for injection
for cattle, pigs and sheep
(Tulathromycin)**

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



PRODUCT SUMMARY

EU procedure number	ES/V/0423/001/DC
Name, strength and pharmaceutical form	Labixxin 100mg/ml solution for injection for cattle, pigs and sheep
Applicant	Labiana Life Sciences S.A.
Active substance(s)	Tulathromycin
ATC vetcode	QJ01FA
Target species	Cattle, pigs and sheep
Indication for use	<p><u>Cattle</u></p> <p>Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis susceptible to tulathromycin. The presence of the disease in the group must be established before the product is used.</p> <p>Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis susceptible to tulathromycin.</p> <p><u>Pigs</u></p> <p>Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica susceptible to tulathromycin. The presence of the disease in the group must be established before the product is used. The veterinary medicinal product should only be used if pigs are expected to develop the disease within 2–3 days.</p> <p><u>Sheep</u></p> <p>Treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent Dichelobacter nodosus requiring systemic treatment.</p>

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



PRODUCT INFORMATION

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



SUMMARY OF ASSESSMENT

Legal basis of original application	Generic application in accordance with Article 18 of Regulation (EU) 2019/6 as amended.
Reference product (RP)	Draxxin 100 mg/ml solution for injection for cattle, pigs and sheep
Marketing authorisation holder	ZOETIS BELGIUM S.A
MS where the RP is or has been authorised	N/A
Marketing authorisation number	EU013 IP
EU procedure number	EU/2/03/041
Date of authorisation	13/11/2003
Date of completion of the original decentralised procedure	20/09/2023
Concerned Member States for original procedure	HR
Concerned Member States for subsequent recognition procedure	N/A
Withdrawn CMS during original decentralised procedure	N/A

*Please be aware that certain parts of the dossier may be varied and consequently be subject to protection of technical documentation – for these and other changes of reference ability to parts of the dossier, please see chapter POST-AUTHORISATION PROCEDURES

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



1. SCIENTIFIC OVERVIEW

The veterinary medicinal product (VMP) is produced and controlled using validated methods and tests, which ensure the consistency of the VMP released on the market.

It has been shown that the VMP can be safely used in the target species; the reactions observed are indicated in the SPC.

The VMP is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the VMP was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



2. QUALITY DOCUMENTATION (physicochemical, biological or microbiological information)

2.A. Product description

The VMP contains tulathromycin (100 mg/ml) as active substance, monothioglycerol as antioxidant and the excipients citric acid, propylene glycol, hydrochloric acid dilute, sodium hydroxide and water for injections. The VMP is a clear colourless to slightly yellow or slightly pink solution, free from visible particles.

The VMP is presented in colourless glass (type I Ph. Eur.) vials of 20 ml, 50 ml, 100 ml and 250 ml closed with a fluoropolymer coated chlorobutyl rubber stopper and sealed with aluminium cap.

The VMP is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

2.B. Description of the manufacturing method

The VMP is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the VMP have been presented in accordance with the relevant European guidelines.

2.C. Production and control of starting materials

The active substance is tulathromycin, an established active substance which is not described in a pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The information on the active substance is provided according to the Active Substance Master File (ASMF) procedure.

Satisfactory TSE information has been provided in compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products.

2.D. Control tests carried out on isolated intermediates during the manufacturing process

Not applicable.

2.E. Control tests on the finished product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification and their limits have been justified and are considered appropriate to adequately control the quality of the VMP.

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

2.F. Stability tests

Stability data on the active substance tulathromycin have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the VMP throughout its shelf life (3 years) when stored under the approved conditions.

Data submitted on in-use stability studies are considered sufficient to support an in-use shelf life of 28 days after broaching.

2.G. Other information

Not applicable.

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



3. SAFETY DOCUMENTATION (safety and residues tests)

3.A. Safety tests

Pharmacological studies

As this is a generic application according to Article 18 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, results of pharmacological tests are not required.

Toxicological studies

As this is a generic application according to Article 18 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, results of toxicological tests are not required.

User safety

The applicant has provided a user safety assessment in compliance with the relevant guideline, which shows that no difference in terms of risk to the user is to be expected between candidate and reference VMP.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the VMP.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the initial predicted environmental concentration in soil for intensively (PEC_{soil}, initial worst case = 10,86 µg/kg for Weaner pig) and extensively (PEC_{soil}, initial worst case = 5.225 µg/kg µg/kg for beef cattle) reared animals is less than 100 µg/kg.

3.B. Residues documentation

Residue tests

No residue depletion studies were conducted because bioequivalence to the reference VMP has been demonstrated.

Maximum Residue Limits

Tulathromycin is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



Pharmacologically active substance(s)	Marker residue	Animal species	MRLs (µg/kg)	Target tissues	Other provisions
Tulathromycin	(2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-ylohexopyranosyl]oxy]-1-oxa-6-azacyclopent-decan-15-one expressed as tulathromycin equivalent	Ovine Caprine	450 250 5400 1800	Muscle Fat Liver Kidney	Not for use in animals from which milk is produced for human consumption
		Bovine	300 200 4500 3000	Muscle Fat Liver Kidney	
		Porcine	800 300 4000 8000	Muscle Skin and fat in natural proportions Liver Kidney	

Withdrawal Periods

Based on the data provided above, the following withdrawal periods are justified.

Cattle (meat and offal): 22 days.

Pigs (meat and offal): 13 days.

Sheep (meat and offal): 16 days.

Not authorised for use in animals producing milk for human consumption.

Do not use in pregnant animals, which are intended to produce milk for human consumption, within 2 months of expected parturition.

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



4. EFFICACY DOCUMENTATION (preclinical studies and clinical trials)

As this is a generic application according to Article 18 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, efficacy studies are not required. The efficacy claims for this VMP are equivalent to those of the reference VMP.

4.A. Pre-Clinical Studies

No pre-clinical studies were performed.

4.B. Clinical trials

No clinical trials were performed.

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



5. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the VMP is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the VMP for humans and the environment is acceptable.

Labixxin 100mg/ml solution for injection for cattle, pigs and sheep	ES/V/0423/001/DC
Labiana Life Sciences S.A	DCP
Publicly available assessment report	



POST-AUTHORISATION PROCEDURES

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the VMP. The current SPC is available in the Union Product Database (UPD).

This section contains information on significant changes, which have been made after the original procedure, which are important for the quality, safety or efficacy of the VMP.

None.